A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, December 19, 2016
Lack of natalizumab concentration increase before PML argues against extending dosing interval
Key clinical point: Extending the dosing interval of natalizumab
to a maximum of 8 weeks in order to lower its serum concentration may not do
anything to reduce the risk of PML.
Major finding: A total of 10 control patients had a mean
natalizumab serum concentration of 23.8 mcg/mL, which was in the same range as
the 18.9 mcg/mL level observed in 5 patients before a diagnosis of PML.
Data source: A comparison of 5 patients with PML and 10 age-
and sex-matched controls from a prospective cohort of 219 patients with
relapsing-remitting MS who were treated with natalizumab at one center.
Disclosures: The study received support from the Brain
Foundation Netherlands. Five of the authors reported financial ties to various
pharmaceutical companies that market MS drugs, including Biogen, which markets